- Home
- EHAB vs TSHA Comparison
EHAB vs TSHA Comparison
Compare EHAB & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHAB
- TSHA
- Stock Information
- Founded
- EHAB 2014
- TSHA 2019
- Country
- EHAB United States
- TSHA United States
- Employees
- EHAB N/A
- TSHA N/A
- Industry
- EHAB Hospital/Nursing Management
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- EHAB Health Care
- TSHA Health Care
- Exchange
- EHAB Nasdaq
- TSHA Nasdaq
- Market Cap
- EHAB 401.8M
- TSHA 356.7M
- IPO Year
- EHAB N/A
- TSHA 2020
- Fundamental
- Price
- EHAB $8.80
- TSHA $1.38
- Analyst Decision
- EHAB Hold
- TSHA Strong Buy
- Analyst Count
- EHAB 3
- TSHA 8
- Target Price
- EHAB $8.50
- TSHA $6.63
- AVG Volume (30 Days)
- EHAB 405.3K
- TSHA 1.6M
- Earning Date
- EHAB 03-05-2025
- TSHA 05-13-2025
- Dividend Yield
- EHAB N/A
- TSHA N/A
- EPS Growth
- EHAB N/A
- TSHA N/A
- EPS
- EHAB N/A
- TSHA N/A
- Revenue
- EHAB $1,034,800,000.00
- TSHA $8,333,000.00
- Revenue This Year
- EHAB $5.72
- TSHA N/A
- Revenue Next Year
- EHAB $4.75
- TSHA N/A
- P/E Ratio
- EHAB N/A
- TSHA N/A
- Revenue Growth
- EHAB N/A
- TSHA N/A
- 52 Week Low
- EHAB $6.85
- TSHA $1.17
- 52 Week High
- EHAB $11.69
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- EHAB 52.49
- TSHA 34.93
- Support Level
- EHAB $8.71
- TSHA $1.59
- Resistance Level
- EHAB $9.00
- TSHA $1.87
- Average True Range (ATR)
- EHAB 0.34
- TSHA 0.15
- MACD
- EHAB -0.03
- TSHA -0.01
- Stochastic Oscillator
- EHAB 52.25
- TSHA 24.36
About EHAB Enhabit Inc.
Enhabit Inc provides home health and hospice services in the United States. It offers care where patients prefer it: in their homes. It operates business in two segments: home health and hospice. Its home health segment include a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The hospice segment focuses on the quality of life for patients who are experiencing an advanced, life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates the majority of its revenue from the Home Health segment.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.